Upcoming investor conferences
Innate Pharma announces its financial calendar for 2017
Innate Pharma announces key leadership and corporate governance changes to support next stage of development
Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting reinforcing confidence in our programs
First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile
Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (Nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data
Preliminary Phase 1/2 efficacy data of Lirilumab in combination with Opdivo (Nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck to be presented during SITC meeting
Third quarter 2016 report
Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas
